FDA accepts Velicept's IND to start phase I study for solabegron
The US Food and Drug Administration (FDA) has accepted Velicept Therapeutics' Investigational New Drug (IND) application to initiate a Phase I pharmacokinetic study for a once-daily formulation for solabegron.
Solabegron is a highly potent and selective beta-3 adrenoceptor agonist that is being developed for the treatment of overactive bladder (OAB).
Click on this link for more information.
